A workshop hosted by the International Probiotics Association (IPA) in Washington, DC will tackle some of the key issues facing the probiotics sector, including positions from FDA and FTC on NDIs and claims substantiation.
According to UNPA president Loren Israelsen there has been plenty of recent innovation within the dietary supplement despite complaints to the contrary. But the NDI draft guidance could bring that to a screeching halt.
Under the combined pressure of industry and lawmakers, the federal Drug Enforcement Administration has backed off its emergency listing of kratom to the schedule 1 list of controlled substances.
The NDI draft guidance contains several points that are potentially issues for probiotics, and there appears to be a disconnect with the GRAS (generally recognized as safe) process, says a leading industry expert.
The NDI draft guidance offers a workable road map for companies willing to provide the safety information already called for by law, according to one ingredient supplier.
The Food and Drug Administration has extended the comment period on the updated draft version of the New Dietary Ingredients guidance. The new deadline for comments is Dec. 12.
In response to the recently re-released NDI draft guidance, the Natural Products Association (NPA) has said it is in the later stages of developing a comprehensive safe harbor list of pre-DSHEA dietary ingredients.
More than half (56%) of dietary supplement professionals said they haven’t read the Aug. 11 NDI guidance—and 6% said they haven’t read it, but told their boss that they did.
The drive toward shorter, cleaner labels and the oft-mentioned dearth of innovation in the supplement sphere are both factors of the maturation of the dietary supplement and functional foods industries, according to one expert.
From ingredient combinations to supercritical CO2 extraction to nanotechnology, here are some things to note from the new NDI draft guidance FDA released Aug. 11.
Over the last few years, the FDA has zeroed in on the dietary supplement industry. It has taken numerous actions against dietary supplements where it believes the ingredients pose health risks to the public. This scrutiny continues with the release...
In what has been called an ‘unprecedented’ move, the Food and Drug Administration has initiated a proceeding to take vinpocetine off the market despite a number of successful NDI notifications filed on the ingredient.
